James Patrick Kelly
Executive VP, CFO & TreasurerMr. James Patrick Kelly, CFA, also known as Jim, serves as an Executive Vice President, Chief Financial Officer and Treasurer at Novavax, Inc. since August 2021. He served as Executive Vice-President and Chief Financial Officer at Supernus Pharmaceuticals, Inc. since October 12, 2020 until August 2021. Mr. Kelly joined Supernus Pharmaceuticals, Inc. in October 12, 2020. He served as Executive Vice-President, Chief Financial Officer and Treasurer of Vanda Pharmaceuticals Inc. since February 2017 until March 2020. Mr. Kelly previously served as Senior Vice-President, Chief Financial Officer and Treasurer of Vanda Pharmaceuticals from December 2010 through February 2017 and its Secretary from December 2010 to September 2015 and again from April 2018 to August 2018. He has biopharmaceutical industry experience in finance roles of increasing scope and responsibility. He has been a key member of MedImmune's financial leadership team since 2006. From March 2006 through December 2010, Mr. Kelly was at MedImmune, a biotechnology subsidiary of AstraZeneca Group, first as Director of Sales and Marketing Finance and then as Vice-President and Controller. He was Senior Vice President, Chief Financial Officer and Treasurer at Vanda Pharmaceuticals Inc. from December 2010 to February 2017. From June 2000 to December 2005, Mr. Kelly was at Biogen Idec serving in research and development finance roles of increasing responsibility, most recently as the Director of Planning and Operations. In that role, he was the Finance Leader for the global Development Organization and head of business operations for clinical functions. While at Biogen Idec, Mr. Kelly led the financial management of development and commercial collaborations which included 5 partners, 8 programs, 14 indications. From 1997 to 2000, he was a member of the corporate finance team at Aetna Inc., which team was responsible for mergers and acquisitions and treasury management. During that period he participated in 11 transactions. He began his life sciences career in 1991 with Janssen Pharmaceutical, a division of Johnson & Johnson. Mr. Kelly is a Chartered Financial Analyst and a Member of the Association of Bioscience Financial Officers. He holds his Master of Business Administration degree in Finance from Cornell University and his Bachelor of Sciences degree in Business from the University of Vermont.
Positions
- Company NameNovavax, Inc.Stock CodeNVAXPositionExecutive VP, CFO & TreasurerColleagues
- JCJohn Charles JacobsPresident, CEO & Director
- DMDavid M. MottChairman of the Board of Directors
- MJMark J. CaseyExecutive VP, Chief Legal Officer & Corporate Secretary
- EOElaine O'HaraExecutive VP & Chief Strategy Officer
- RPRichard P. CrowleyExecutive VP & COO
- MGMargaret G. McGlynnIndependent Vice Chairman of the Board of Directors
- RJRichard J. RodgersIndependent Director
- RHRichard Huntington DouglasIndependent Director
